Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
Platform-based drug development has gained traction across the biotechnology industry because of its efficiency and risk management advantages. Soligenix’s development of synthetic hypericin illustrates this “one drug, multiple diseases” model in action. HyBryte is being developed to treat both cutaneous T-cell lymphoma (“CTCL”), a rare form of non-Hodgkin lymphoma that primarily affects the skin, and psoriasis. Modern biopharmaceutical innovation often revolves around a powerful idea: One scientific mechanism can unlock treatments for multiple diseases. Rather than building entirely new molecules for every indication, companies are developing platform technologies that allow a single therapeutic approach to be adapted across conditions. Soligenix…
